Pr. Rachid soulimani, president of AGRESS association, responsible of "Neurodevtox" anr/europe-feder program, responsible of "Arf Tempus, Europe/Tempus program, header of Research Team Neurotoxicology and Development /Inra, University of Lorraine, France.
Extraction of bioactive compounds from plants is often performed using organic solvents that may have a toxic effect on human health and lead to environmental pollution. Recently, a new ecological process for extracting natural active compounds according to their granulometric size called “Differential Controlled Sieving Process” (DCSP) was invented by Agritech (France; Baudelaire, 2013). To validate this technological process, two medicinal plants named ivy (Hedera helix) and figwort (Scrophularia nodosa) were used to assess the effect of DCSP on their well-known pharmacological properties including their cytoprotective and antioxidant potentials. To this end, powders from ivy leaves and figwort aerial parts (20 to 500 µm of particle size) were obtained by DCSP. Hydroalcoholic extracts (HE) of plants were prepared and used as control. Moreover, mouse spleen cells were isolated and the cytotoxicity of all plant preparations (granulometric fractions and HE) was checked by MTT assay at different concentrations. Finally, the intracellular levels of different oxidative markers (ROS, MDA, SOD, CAT and GPx) were measured. For both plants, neither fractions nor extracts exerted a cytotoxic effect on splenocytes. Only granulometric fractions ranging from 50 to 315 µm exhibited an antioxidant effect that was significantly higher than HE. These results were consistent with chemical analyses showing higher content of some main active compounds of ivy (α-hederin and hederasaponin-C) and figwort (iridoid glycosides) in the same granulometric classes, compared to their HE. These data suggest that DCSP improves the biological activities of ivy and figwort and leads to a differential distribution of bioactive compounds.
Chan Young, Kwon is a Korean Medicine Doctor (KMD) and a specialist on oriental neuropsychiatry. He received a master’s degree from Kyung Hee University in 2016, and he’s doing his doctoral studies. He has published several papers about neuropsychiatric subjects including posttraumatic stress disorder (PTSD), depression, headache, and emotion freedom technique (EFT). And he participated in the process of developing KM clinical practice guideline on depression.
To treat generalized anxiety disorder (GAD), some western medications (WM) and psychotherapies are being used. However problems about inadequate efficacy, side effects of the psychopharmacologic agents, and drug resistance are still present. The purpose of this review is to assess the efficacy and safety of oriental herbal medicine (OHM) for GAD. Twelve databases were searched for randomized controlled trial (RCT) of OHM for GAD, from inception to August 2016. Two authors conducted the trial inclusion, extracted data from the included trials, and assessed the risk of bias, independently. The primary outcomes were change in anxiety score and Toxic Exposure Surveillance System (TESS) score. A total of 11,039 studies were identified, and 111 RCTs were met our inclusion criteria. Our meta-analyses showed that OHM appeared to be more effective than placebo (5 RCTs; MD, -7.01; 95% CI, -11.03 to -3.00) and WM (45 RCTs; MD, -1.27; 95% CI, -2.06 to -0.48) as assessed by the Hamilton Anxiety Rating Scale (HAMA); OHM appeared to be more safe than WM (11 RCTs; MD, -3.09; 95% CI, -5.80 to -2.23) as assessed by TESS. Moreover when OHM was prescribed with WM, the anxiolytic effect was superior than WM alone (28 RCTs; MD, -2.84; 95% CI, -3.49 to -2.20). Our findings indicate that OHM is safe and potentially effective to relieve anxiety symptoms of GAD patient. However as the methodological quality of included trials are relatively poor, well-designed and rigorous RCTs are needed to support this findings.